RT Journal Article SR Electronic T1 Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.06.30.20142570 DO 10.1101/2020.06.30.20142570 A1 Mark J. Mulligan A1 Kirsten E. Lyke A1 Nicholas Kitchin A1 Judith Absalon A1 Alejandra Gurtman A1 Stephen Lockhart A1 Kathleen Neuzil A1 Vanessa Raabe A1 Ruth Bailey A1 Kena A. Swanson A1 Ping Li A1 Kenneth Koury A1 Warren Kalina A1 David Cooper A1 Camila Fontes-Garfias A1 Pei-Yong Shi A1 Ӧzlem Türeci A1 Kristin R. Tompkins A1 Edward E. Walsh A1 Robert Frenck A1 Ann R. Falsey A1 Philip R. Dormitzer A1 William C. Gruber A1 Uğur Şahin A1 Kathrin U. Jansen YR 2020 UL http://medrxiv.org/content/early/2020/07/01/2020.06.30.20142570.abstract AB In March 2020, the WHO declared a pandemic of coronavirus disease 2019 (COVID-19), due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 With >8.8 million cases and >450,000 deaths reported globally, a vaccine is urgently needed. We report the available safety, tolerability, and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose escalation study among healthy adults, 18-55 years of age, randomized to receive 2 doses, separated by 21 days, of 10 μg, 30 μg, or 100 μg of BNT162b1, a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD. Local reactions and systemic events were dose-dependent, generally mild to moderate, and transient. RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titers in sera increased with dose level and after a second dose. Geometric mean neutralizing titers reached 1.8-to 2.8-fold that of a panel of COVID-19 convalescent human sera. These results support further evaluation of this mRNA vaccine candidate.Competing Interest StatementCompeting interests NK, JA, AG, SL, RB, KS, PL, KK, WK, DC, KT, PRD, WG, and KUJ are employees of Pfizer and may hold stock options. US and ÖT are stock owners, management board members, and employees at BioNTech SE (Mainz, Germany) and are inventors on patents and patent applications related to RNA technology. MJM, KL, KN, EW, AF, RF, and VR received compensation from Pfizer for their role as study investigators. CFG and PYS received compensation from Pfizer to perform the neutralization assay. Clinical TrialClinicalTrials.gov identifier: NCT04368728Funding StatementRole of the funding source: BioNTech is the Sponsor of the study. Pfizer was responsible for the design, data collection, data analysis, data interpretation, and writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit the data for publication. All study data were available to all authors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The final protocol and informed consent document were approved by institutional review boards for each of the participating investigational centers This study was conducted in compliance with all International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines and the ethical principles of the Declaration of Helsinki. A signed and dated informed consent form was required before any study-specific activity was performed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual anonymized participant data. See https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information.